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Introduction
Protein ubiquitination affects the fate of target proteins in many essential processes in the cell. The substrate specificity factors of the ubiquitin proteasomal system, the ubiquitin ligases, bind to their substrates and transfer ubiquitin directly or indirectly to their target proteins [1] . The largest class of ubiquitin ligases are the Skp1-Cullin-F-box protein (SCF) and SCF-like complexes. F-box proteins bind to S-phase-kinase-associated-protein-1 (Skp1) via the N-terminal F-box domain and to their substrates via a C-terminal binding domain [2] .
β-transducing-repeat-containing protein (βTrCP) belongs to the family of F-box proteins and was first identified as an interaction partner of the Human Immunodeficiency Virus-1 Vpu protein [3] . As the F-box protein component of a SCF ubiquitin ligase complex, βTrCP is involved in major regulatory mechanisms such as cell cycle progression, metabolism, development, and immunity. Human cells contain two βTrCP proteins, βTrCP1 encoded by BTRC, and βTrCP2 encoded by FBXW11, also known as HOS or βTRCP2 [1, 4] . The E3 substrate binding domain of βTrCP is the WD40 domain repeat motif, which contains seven WD40 repeats that are structured into a sevenbladed propeller [1] . For Vpu, it has been shown that all repeats are required for optimal substrate binding [5] .
The cullin proteins (numbered 1-5, and 7) act as molecular scaffolds in the SCF complexes and bind with their N-terminus to Skp1 and with their C-terminus to RING-finger protein Rbx1 and to specific ubiquitin conjugating enzymes (E2) [6] . In case of the interaction between the SCF-complex and the E2 Cdc34, the rapid assembly and disassembly of the E2-E3 complex facilitates ubiquitin chain synthesis. Moreover, residues important for the dynamics of the complex are conserved, suggesting that all SCF complexes and their E2's have the same mechanism of chain assembly [7] .
A large number of studies show that the structural requirements for substrate recognition is not overly stringent, and conforms to a linear motif of 6-9 amino acids starting with two acidic amino acid residues followed by a small amino acid and another acidic moiety in the last position. In β-catenin and IκB (inhibitor of NFκB), the second and last positions constitute phosphorylated serine residues. Upstream of this motif, one or several lysine residues serve as ubiquitin acceptors [8] [9] [10] .
The F-box and WD40 domains of the two isoforms, βTrCP1 and βTrCP2, are highly identical, 86 and 75%, respectively [11, 12] . Moreover, their WD40 domains show very similar electrostatic surface properties, with a conservation of the central groove covered by positively charged amino acids that interact with the negatively charged residues in the destruction motif of target proteins [13] . Indeed, many studies show that the βTrCP isoforms are functionally redundant. This has been reported for the degradation of Wee1, IκB, Per1 and the RE1-silencing transcription factor (Rest) [14] [15] [16] [17] . Conversely, specificity exists for the early mitotic inhibitor 1 (Emi1) that explicitly requires βTrCP1 for its degradation [18, 19] . In addition, genetic evidence from gene knock-out experiments in mice shows that βTrCP2 is essential in early development while deletion of βTrCP1 does not affect viability but impairs spermatogenesis and reduces fertility [18] . This implies that, although both isoforms occur in all or most cells, they have marked features that cause these differences. The phenotypes may arise from differences in local concentrations, substrate binding, turnover, or expression. However, all these parameters are inferred from structural differences in the proteins. Therefore, we have investigated the different βTrCP isoforms and their splice variants. In humans, two splice variants of βTrCP1, α and β (without the second exon), and three of βTrCP2, α, β, (with an alternative second exon) and γ (without the second exon), are predicted to exist.
In this study, we show for the first time the localisation of endogenous βTrCP1 and 2 isoforms and splice variants using isoformspecific antibodies. We find that βTrCP1 and 2 are both present in the nucleus as well as in the cytosol, whereas a striking difference in localisation between two splice variants of βTrCP2 was observed: while βTrCP2γ resides exclusively in the cytosol, βTrCP2β is solely detectable in the nucleus.
Materials and methods

Cell culture and transfections
HEK293 cells were cultured in 4.5 g/l glucose (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen), 100 units/ml penicillin, 0.1 mg/ml streptomycin (both Invitrogen). HEK293 cells, stably expressing the Tet-repressor (HEKTR), were a gift of Dr. Madelon Maurice and were maintained in DMEM with 4.5 g/l glucose, supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin and 12 μg/ml Blasticidin-S (MP Biomedicals). HEKTR cells, stably expressing βTrCP1 or 2 (upon 1 ng/ml doxycyclin addition) (HEKTR_iTrCP), were cultured in the maintenance medium for HEKTR cells, supplemented with 170 μg/ml zeocin (Invitrogen). HEKTR_iTrCP cells that were either stably transfected with GHR (HEKTR_GHR_iTrCP1 or 2), were cultured in HEKTR_iTrCP maintenance medium, supplemented with 600 μg/ml geneticin (Invitrogen).
Transfections, DNA constructs and siRNA
Wild type GHR in pcDNA3.1, GFP siRNA and βTrCP siRNA were described before, as were wild type Flag-βTrCP2, Flag-βTrCP2(ΔWD40), βTrCP2(WD40), βTrCP2(ΔF) and βTrCP2(ΔD) [20] . Inducible βTrCP1β and 2α were constructed by cloning βTrCP1β and βTrCP2α into pcDNA4/ TO (Invitrogen), Tet-repressor is in pcDNA6 and GST-βTrCP1β (1-93) and GST-βTrCP2α (1-68) are in pGEX1λt. βTrCP1α (1-167) (from clone IRAKp961E0762Q2 obtained from RZPD) and β (1-131) were expressed in a pcDNA4/TO vector. EST clones containing N-terminal fragments of TRCP2β and γ were a gift from Dr. Gabor Gyapay (Genoscope). DNA transfections were performed using FuGene6 (Roche) and siRNA transfections with lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Antibodies and materials
Anti-GHR(B) was described before [21] . Anti-Flag polyclonal and anti-Myc monoclonal were from Sigma. Leptomycin B, used for 12 h at 10 ng/ml, was purchased from Sigma. Cycloheximide was bought from ICN and was used at 100 μg/ml. Doxycyclin was obtained from Clontech. Biotin-GH was described before [22] .
Antibody generation and affinity purification
GST fusion proteins of residues 1-93 of βTrCP1β and residues 1-68 of βTrCP2α were injected into rabbits and antisera were obtained. We affinity purified the antisera using CNBr activated Sepharose-4 beads (Pharmacia), according to the manufacturer's manual.
Preparation of nuclear, cytosolic and membrane fractions
Subconfluent cells were collected with trypsin-EDTA (Invitrogen) and washed with phosphate-buffered saline (PBS), after which the cells were washed two times in hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulphonyl fluoride (PMSF), 10 μg/ml leupeptin and 10 μg/ml aprotinine), after which the cells were incubated in hypotonic buffer on ice for 10 min. The cells were dounced 50 times with a B-type pestle, after which the lysates were centrifuged for 5 s at 16,000 ×g. The supernatant was fractionated into a cytoplasmic and a membrane fraction by centrifugation at 100,000 ×g for 1 h. The pellet was washed 2 times with hypotonic buffer and designated as the nuclear fraction.
Immunofluorescence and confocal microscopy
HEKTR_GHR_iTrCP1 or 2 cells were grown on cover slips. The cells were washed and fixed with 3% paraformaldehyde in 0.1 M sodiumphosphate buffer pH 7.4. After washing with PBS, the cells were incubated with 0.02 M NH 4 Cl for 5 minutes. Subsequently, cells were incubated with 0.2% TritonX-100 for 5 min, followed by three washes with PBS. 0.5% bovine serum albumin (BSA) was added for 15 min and the primary antibody in 0.5% BSA was left on the cells for 30 min. The cells were washed with 0.5% BSA and incubated with Alexa goat anti-rabbit 488 (Molecular probes) for 30 min. After washing with 0.5 mg/ml BSA in PBS and PBS, the cells were mounted with mowiol and analysed using a confocal microscope.
Cell lysis, immunoprecipitation and biotin-GH pull down
Cell lysates were prepared by washing the cells with cold PBS, after which the cells were lysed with 1% Triton X-100, 1 mM EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF in PBS for 15 min. For the turnover experiments, the cell lysates were prepared by incubating the cells in a buffer containing 1% sodium dodecyl sulphate (SDS), 1 mM EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF in PBS for 10 min at 100°C. The lysates were centrifuged for 5 min and the supernatants were used for immunoprecipitations by incubation with anti-myc for 2 h followed by incubation of 45 min with protein A agarose beads. Biotin-GH pull down was performed by incubating the lysates for 1 h with biotin-GH, followed by a 30-min incubation with streptavidin agarose beads. Lysates, immunoprecipitates and pull down samples were subjected to SDS-PAGE and western blotting, after which the membranes were detected with the indicated antibodies. Western blots were analysed using an Odyssey infrared imaging system and quantified using Odyssey software (Li-Cor Biosciences, Lincoln, NE).
Tissue profiling and RT-PCR
Tissue profiling was done using Clontech Human Multiple Tissue cDNA panels I and II and PCR was done according to the user's manual. The following primers were used: βTrCP1 forward primer GATCGGATCCATG-GACCCGGCCGAGGCG, βTrCP1 reverse primer: GTACGCGGCCGCGTGCC-CATGTTGGTAATGAC, βTrCP2 forward primer TTTGGATCCATGG-AGCCCGACTCGGTGATTGAGGAC and βTrCP2 reverse primer GTACGCGGCCGCATGACCATGCTGATAATGAC. The same primers were used to perform a RT-PCR for βTrCP1 and 2 on the RNA isolated from HEK293 cells. DNA products were verified by direct sequencing.
Results
Detection of βTrCP1 and 2 isoforms by specific antibodies
In order to identify differences between endogenous βTrCP isoforms and splice variants that might account for their functional differences, we generated isoform-specific antibodies. The schematic structure of βTrCP, depicted in Fig. 1A , shows a variable domain in the N-terminus. Therefore, we selected the variable domains of βTrCP to generate antibodies specific for either βTrCP1 or 2. The splice variants are identifiable by their differences in molecular weight. To test antibody sensitivity and specificity, we prepared nuclear and cytosolic fractions from HEKTR cells and analysed the samples on western blot. Fig. 1B shows expected bands of~60 kD and 50 kD for endogenous βTrCP1 and 2, respectively, indicating that the antibodies are capable of detecting endogenous βTrCP. To determine whether the observed bands are specific, we depleted the cells for βTrCP with a siRNA probe directed against both βTrCP1 and 2 and a control siRNA (GFP). As shown in Fig. 1B , the bands detected in GFP-silenced cells completely disappeared in βTrCP-silenced cells. Importantly, the band detected by anti-βTrCP1 was not detected by anti-βTrCP2 and vice versa, which shows that the antibodies are isoform-specific. With the βTrCP2 antiserum, we detected one abundant background band that was present only in the nuclear fraction, which was not silenced with βTrCP siRNA. These results clearly indicate that the antibodies are specific and can be used to identify differences in cellular localisation, substrate binding and turnover.
Endogenous and exogenous βTrCP1 and 2 localise to both nucleus and cytosol
One obvious explanation for substrate-specificity of βTrCP1 and 2 is a different localisation. To localise the isoforms in the cell, we used HEKTR-cells that express either βTrCP1 or 2 from a doxycyclin-inducible DNA construct. After treatment with doxycyclin, we stained with affinity-purified βTrCP1 and 2 antibodies and visualised the cells using confocal microscopy. Fig. 2A shows that induction of exogenous βTrCP1 and 2 resulted in a strong increase in signal intensity, indicating that the antibodies work after formaldehyde fixation of cells. The vehicle-treated cells show that endogenous βTrCP1 and 2 both localise to both the cytoplasm and the nucleus. The same localisations were detected for exogenous (doxycyclin-induced) βTrCP. Leptomycin B treatment, which results in inhibition of nuclear export via XPO1/CRM1, resulted in localisation of both (endogenous) isoforms in the nucleus (Fig. 2B) , indicating that they shuttle between the nucleus and the cytosol. Together, these results show no differences for the localisation of βTrCP1 and 2 isoforms. Both endogenous and exogenous βTrCP isoforms are present in the nucleus and the cytoplasm. The effect of leptomycin also illustrates that the specificity of the antibodies as the treatment reduces labelling of the cytosol to background values.
βTrCP splice variants localise differently within the cell
In a previous study with mouse cells, 8 splice variants for both mouse βTrCP1 and 2 were identified. To determine the occurrence of βTrCP splice variant mRNAs in human HEKTR-cells, we performed RT-PCR and detected two abundant human splice variants for βTrCP1 (α and β) and two for βTrCP2 (β and γ) (Fig. 3A) . For βTrCP1, one extra low abundant splice variant was detected, which we named βTrCP1α'. Surprisingly, βTrCP2α RNA, used in most overexpression studies, was not detected in HEKTR cells.
As immunofluorescence was unable to distinguish the different βTrCP splice variants, we performed cell fractionation. In nuclear and cytosolic fractions of doxycycline-inducible HEKTR_iTrCP1 or 2 cells we detected only one endogenous splice variant of βTrCP1, which migrated as exogenous βTrCP1β (Fig. 3B) . As the mRNA of both βTrCP1α and β splice variants are produced in HEK293 cells (Fig. 3A) and the βTrCP1 antibody recognises both βTrCP1α and β variants (Fig. 3D) , it might be that the difference in molecular weight is too small to distinguish βTrCP1α from β on western blot. Another explanation would be that the protein βTrCP1α is unstable. We conclude from our immunofluorescence data that endogenous βTrCP1 and exogenous βTrCP1β localise to both the cytoplasm and the nucleus.
We detected two endogenous βTrCP2 isoforms, of which the fastmigrating one was present in the cytosol and the slow-migrating one was found in the nucleus. Since the exogenous βTrCP2 is the α-variant, the endogenous faster-migrating TrCP2 splice variants are very likely the β and γ variants. The absence of endogenous βTrCP2α is supported by the RT-PCR data (Fig. 3A) . This is in agreement with a previous study in mouse tissues, in which it was shown that the most commonly used βTrCP2α splice variant is expressed to a very low extent [23] . Together, the results present evidence that the βTrCP2 antibodies recognise both the β and γ splice-variants as they contain exactly the same amino acid sequences that were present in the 2α-fusion protein injected in the rabbits.
Since several cell surface signalling receptors are βTrCP substrates, we investigated whether βTrCP that is outside the nucleus, is membrane-bound or cytosolic. As shown in Fig. 3C and already indicated by the granular appearance in Fig. 2B , endogenous βTrCP1 and 2 are mainly attached to membranes rather than existing free in the cytosol. In contrast, membrane-bound and cytosolic exogenous βTrCP1 and 2 levels are similar, probably because the substrates at the plasma membranes are saturated with βTrCP due to high expression levels of βTrCP.
Immunocytochemical data suggest that βTrCP1 is mainly responsible for ubiquitination of nuclear substrates, including ATF4 and Emi1 [19, 24] , while βTrCP2 is also involved in cell surface receptor degradation [20, 25] . Since βTrCP2α localises to both nucleus and cytosol, we chose this variant to define a localisation motif or domain and constructed several Flag-tagged βTrCP mutants: lacking either the F-box (ΔF), the dimerization domain (ΔD) or the WD40 domain (ΔWD40) or only the WD40 domain (WD40). Fig. 3E clearly shows that wild type βTrCP2α is highly abundant in the nucleus compared to the cytosol. In contrast, the ΔWD40 mutant shows an equal distribution between nucleus and cytosol, demonstrating that the WD40 domain is important for nuclear localisation. As wild type βTrCP, the WD40 domain itself localised to the nucleus. In fact, all mutant βTrCP species with an intact WD40 domain distributed equally, supporting the notion that the localisation of βTrCP is dictated by the location of its substrates.
Both βTrCP1 and 2 are stable proteins
As it has become clear that ubiquitin ligases can auto-ubiquitinate, the stability of ubiquitin ligases is an important parameter in major regulatory processes. βTrCP2 is stabilised in the presence of phosphorylated substrates [26] . To determine the stability of endogenous βTrCP1 and 2, we treated HEKTR cells with cycloheximide and quantified endogenous βTrCP1 and 2 levels after different chase periods. Fig. 4 clearly shows that the turnover of both βTrCP1 and 2 is low, since after four and a half hours not even half of the proteins were degraded. We conclude that the half lives of endogenous βTrCP1 and 2 isoforms are similar, demonstrating that the turnover does not contribute to their differential cellular function.
Tissue distribution of RNA levels of splice variants of βTrCP1 and 2
Based on the finding that splice variants localise differently in cells, we speculated that different cell types use differential alternative splicing to regulate the level of specific variants of βTrCP in cells. Therefore, we performed a RT-PCR on a variety of tissues and determined whether their mRNA levels varied among these tissues. Fig. 5A shows that three mRNAs of βTrCP1 were detectable instead of the predicted two, just like we observed in Fig. 3A . These data are in agreement with a study from Seo et al. [23] . Out of the three detected mRNAs, two are very abundant in several tissues (α and β), whereas the α' variant is predominantly expressed in testis. βTrCP1 mRNA levels vary considerably in different tissues (Fig. 5A) , so it might be that different cell types do not equally depend on the various splice variants. For βTrCP2, we detected four mRNA splice variants; β, γ and two splice variants indicated with asterisks (Fig. 5B) . The mRNAs of these two splice variants were also detected by Seo et al. [23] , but we did not detect either of them at the protein level, suggesting that the proteins are unstable. Although the signals were low for βTrCP2β and γ (Fig. 5B) , the RNA expression patterns of the tested tissues seem to differ, suggesting that regulation of βTrCP2 mRNA splicing might be a mechanism for cells to regulate βTrCP2 splice variant levels.
Discussion
The importance of SCF βTrCP is reflected by its involvement in key processes in the cell, such as the NFκB and the Wnt signalling pathways. Many studies have been performed in order to identify which βTrCP isoform acts on a given substrate. Because of the lack of antibodies recognizing endogenous βTrCP, these studies were all done with exogenous βTrCP, in particular βTrCP1β and 2α. Overexpression of a protein might result in aberrant localisation, substrate binding characteristics or half life compared to the endogenous protein. As a consequence of using exogenous βTrCP, most studies investigated only one particular splice variant. Our isoform-specific antibodies enabled a precise study of localisation, substrate affinity and turnover of endogenous βTrCPs. We found that both endogenous βTrCP1 and 2 isoforms are localised in the nucleus as well as in the cytosol. However, whereas endogenous βTrCP2β was exclusively found in the nucleus, endogenous βTrCP2γ was found only in the cytosol. Moreover, we showed that the substrate binding domain is an important factor for nuclear localisation. However, in case of the different location of βTrCP2β and 2γ this cannot be contributed to their (identical) WD40 domain. The variable N-termini might play a role as well. Both endogenous βTrCP1 and 2 isoforms that are located outside the nucleus are mainly membrane-localised. As the substrate binding domain appears the dominant localisation factor, it is tempting to speculate that most of the processes outside the nucleus that involve βTrCP occur membrane-associated. In contrast, exogenous βTrCP is distributed equally over cytosol and membrane fractions, indicating that high βTrCP expression levels saturate the βTrCP substrates located at the membrane with βTrCP. Excess βTrCP that does not encounter a substrate on the membrane will mislocalise in the cytosol. Fig. 3 . Expression pattern and cellular localisation of βTrCP2 splice variants. (A) RNA was isolated from HEK293 cells and a RT-PCR with primers specific for either βTrCP1 or 2 was performed. DNA from known splice variants was used as positive control. (B) HEKTR_iTrCP1 and HEKTR_iTrCP2 cells were treated with and without doxycyclin followed by the preparation of cytosolic (C) and nuclear (N) fractions. The fractions were analysed on western blot using affinity-purified anti-βTrCP1 or 2. On the right, the splice variants are indicated. (C) HEKTR_iTrCP1 and HEKTR_iTrCP2 cells were treated with doxycyclin followed by the preparation of nuclear (N) and crude cytosolic (CC) fractions. The CC fractions were further separated into cytosolic (C) and membrane (M) fractions. The fractions were analysed as in Fig. 3B . On the right, the splice variants are indicated. The data are shown as typical examples of three independently performed experiments. (D) βTrCP1α 1-167 and βTrCP1β 1-131 were expressed in HEKTR cells and detected with anti-βTrCP1. (E) Flag-tagged βTrCP mutants were expressed in HEKTR cells followed by the preparation of cytosolic and nuclear fractions. The fractions were analysed on western blot using anti-Flag followed by quantification using Odyssey software. Data are displayed as mean values of three experiments ± SD. The identified differences in the localisation of βTrCP isoforms and splice variants suggest that their regulation is important, especially since βTrCP binds concentration-dependently to some substrates instead of recognising the phosphorylated DSGXXS motif. This principle of concentration-dependent βTrCP binding implies that uncontrolled βTrCP expression might result in the development of tumours, because many βTrCP substrates are key players in the regulation of many cellular processes that are related to cell division and cancer [27] . In GHR, βTrCP binds to the endocytosis motif (DDSWVEFIELDIDD) without any modifications and its ligase activity probably depends mainly on the cytosolic concentration of the βTrCP2γ variant. GH stimulation of the GHR results in an elevated Insulin-like Growth Factor-I (IGF-I) level, which has been associated with a number of cancers. IGF-I levels can be reduced by blocking GH-binding to GHR or by upregulation of βTrCP2γ [28] . The tumour suppressor TAp63γ also seems to bind βTrCP without upstream action of a kinase. In contrast to many other substrates, βTrCP binding stabilises TAp63γ, resulting in G1 cell cycle arrest [29] . In such conditions, uncontrolled βTrCP expression could result in improper regulation of the cell cycle and cancer.
Despite the high substrate diversity, it has been suggested that βTrCP is tumour-promoting and is considered an oncogene. This is reflected by an increased expression of βTrCP in a variety of cancers, whereas mutations in βTrCP are rarely found in human tumours and primary cancers. Striking examples are hepatocellular carcinomas, which show constitutive NFκB activation together with high βTrCP levels [29] [30] [31] . In addition, some cancers are specifically associated with one of the βTrCP isoforms, like βTrCP1 in hepatoblastomas and colorectoral cancers and βTrCP2 in breast/gastric and prostate cancers. Fig. 5 shows that different cell types have differences in βTrCP splice variant mRNAs, suggesting that also differential expression of βTrCP splice variants might be relevant for the development of cancers. Not only expression of the functional, but also of the non-functional βTrCP splice variants is important for a given substrate. βTrCP variants that bind to, but are not functional towards a given substrate might act as dominant-negative. Another way of regulating βTrCP isoform levels might be binding of the WD40 domain of βTrCP1 and not 2 to pseudosubstrate hnRNP-U [32] . Possibly, more proteins with a similar function are expressed in cells. In addition, proteins can regulate βTrCP expression in cells, which has been shown for BRAF in human melanoma cells [29] .
βTrCP acts within the SCF complex and requires the other SCF components for its activity. The high levels of βTrCP observed in tumours suggest that βTrCP is the limiting factor for activity of the SCF complex. This idea is supported by the fact that βTrCP overexpression in cells often results in accelerated degradation of its substrates, indicating that the other SCF components are not limiting. Together, we conclude that localisation is different between βTrCP variants, suggesting that this parameter is important for their function. The presented findings on βTrCP are important to understand the mechanism of action of βTrCP and its role in cancer.
